Gait characteristics in people with cognitive impairment - the relationship between step length and cadence by Knapstad, Mari Kalland
 
Gait characteristics in people with cognitive 
impairment – the relationship between step 














Masterprogram i helsefag, fysioterapivitenskap, 
Institutt for global helse og samfunnsmedisin 
Det medisinsk-odontologiske fakultet 





My grandmother was diagnosed with dementia when I was in my intern year, finishing my 
physiotherapy education. During my many visits at her home and eventually nursing home, I 
observed how this type of disease affected not only her, but also everyone around her. She 
deteriorated quickly, not only mentally but also physically. I took a particular interest in 
dementia, as I learned how little we actually know about it. After several talks and 
encouragement from my friend Dr. Lasse Giil, I decided that I wanted to find out more about 
the relationship betweem gait function and dementia.  
 
Writing this thesis has been an interesting process with an extreme learning curve and 
moments of both despair and prosperity. There are several people I have to thank for all the 
help along the way. First of all, my two supervisors Ingvill Fjell Naterstad and Rolf Moe-
Nilsen deserves a huge thank you for all their knowledge and feedback. I would like to thank 
Arne Nakling, geriatrician at Betanien Hospital for excellent cooperation and patient access. In 
addition, I would like to thank the librarian Regina Küfner Lein for helping me with research in 
databases. My good friend Thomas Olsen deserves a thank you for all the multiple feedbacks 
on assignments and encouraging words in frustrating times.  
 
Last but not least I want to thank my cohabitant Silje Vedvik for putting up with me this year 












Background: Approximately 70 000 people in Norway are suffering from some form of 
dementia. Gait and balance impairment in patients with Alzheimer’s disease has been 
recognized for years. Reduced walking speed has been observed not only in patients with 
Alzheimer’s disease, but also patients with mild cognitive impairment. However, the step 
length cadence relationship (walk ratio) is yet to be studied in individuals with cognitive 
impairment. Walk ratio has been suggested as a more specific variable than gait speed, as it 
says something about the quality of how we walk.  
 
Aim: The first aim of the thesis was to explore the association between the minimal mental 
state examination (MMSE)-score and walk ratio by reviewing relevant literature. The second 
aim was to see if walk ratio can predict group membership between participants with subjective 
cognitive impairment, mild cognitive impairment and healthy controls.  
 
Methods: A literature review of studies where either walk ratio or spatiotemporal gait 
parameters was reported in populations of cognitive impaired old persons was conducted. In 
addition, a cross-sectional trial with a 10-meter gait assessment for participants with subjective 
cognitive impairment, mild cognitive impairment and healthy controls was conducted.  
 
Results: The literature review yielded a strong correlation between walk ratio and MMSE – 
score (r = 0.69). Linear regression showed that age did not contribute significant to the model. 
The cross-sectional trial showed that walk ratio could not predict group membership to either 
mild cognitive impairment or subjective cognitive impairment. However, a decrease in velocity 
was predictive of both subjective cognitive impairment (OR = 0.967 95% CI 0.938 to 0.997, 
P = 0.03) and mild cognitive impairment (OR = 0.963, 95% CI 0.930 to 0.996, P = 0.03).  
 
Conclusion: There was a strong association between the MMSE – score and walk ratio. In 
addition, a decrease in velocity seems to be predictive of both mild cognitive impairment and 
subjective cognitive impairment. These findings support the fact that there is an association 
between degree of cognitive impairment and gait function and that gait impairment can be 
found in early stages of dementia.   
Sammendrag  
Bakgrunn: Rundt 70 000 mennesker i Norge har en form for demens. Nedsatt gangfunksjon 
og balanse har lenge vært kjent hos pasienter med Alzheimers sykdom. Lav ganghastighet har 
blitt observert hos pasienter med Alzheimers sykdom, men også hos pasienter med mild 
kognitiv svikt. Forholdet mellom steglengde og kadens (gangratio) har så langt ikke blitt 
undersøkt hos pasienter med kognitiv svikt. Gangratio blir sett på som en mer spesifikk 
variabel enn ganghastighet, da den forteller mer om hvordan vi går og ikke bare hastigheten.  
 
Mål: Det førte målet med oppgaven var å undersøke sammenhengen mellom the minimal 
mental state examination (MMSE) – score og gangratio ved en gjennomgang av relevant 
litteratur. Det andre målet var å undersøke om gangratio kunne predikere gruppetilhørighet 
mellom deltakere med subjektiv kognitiv svikt, mild kognitiv svikt og friske kontroller.  
 
Metode: Det ble utført en litteratur gjennomgang av studier der enten gangratio eller 
spatiotemporale gangparameter var rapportert hos eldre mennesker med kognitiv svikt. I tillegg 
ble det utført en tverrsnitt studie med en 10-meter lang gangtest for deltakere med subjektiv 
kognitiv svikt, mild kognitiv svikt og friske kontroller.  
 
Resultat: Litteraturgjennomgangen resulterte i en sterk korrelasjon mellom gangratio og 
MMSE-score (r = 0.69). Liner regresjon viste at alder ikke bidro signifikant til modellen. 
Tverrsnittstudien viste at gangratio ikke kunne predikere gruppetilhørighet for hverken mild 
kognitiv svikt eller subjektiv kognitiv svikt. En nedgang i ganghastighet var derimot prediktivt 
for både subjektiv kognitiv svikt (OR = 0.967 95% CI 0.938 to 0.997, P = 0.03) og mild 
kognitiv svikt (OR = 0.967 95% CI 0.938 to 0.997, P = 0.03). 
 
Konklusjon: Det var en tydelig sammenheng mellom MMSE-score og gangratio. I tillegg var 
en nedgang i ganghastighet predikerende for både subjektiv kognitiv svikt og mild kognitiv 
svikt. Disse resultatene støtter tidligere forskning som rapporterer at det er en sammenheng 
mellom grad av demens og gangfunksjon, i tillegg til at nedsatt gangfunksjon kan oppstå i 
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A syndrome of acquired persistent 
intellectual impairment characterized by 
deterioration in at least three of the 
following domains; memory, language, 
visuospatial skills, personality or 
behaviour, and manipulation of acquired 
knowledge (Kowall and Budson, 2011). 
Alzheimer’s disease  
 
A degenerative brain disorder 
characterized by progressive intellectual 
and behavioral deterioration (Kowall and 
Budson, 2011). 
Mild cognitive impairment 
 
Impairment (adjusted for age and 
education) in one or more domains of 
cognition, with relative sparing of global 
cognitive functions (McGough et al., 
2011). 
Subjective cognitive impairment A clinical stage where subjective memory 
complaints exist in the absence of 
detectable objective cognitive deficits 
(Fonseca et al., 2015). 
Walk ratio 
 
The ratio between step length and cadence 
(Sekiya et al., 1996). 
Gait Cycle  A pattern of movement that start with on 
foot making contact with the floor, and 
continuing until the next occasion when 
the same foot makes contact with the floor 
again (Baker and Hart, 2013). 
Step  
 
The movement of one foot in front of the 
other (Baker and Hart, 2013). 
Stride 
 
A step of one foot followed by another step 
for the other (Baker and Hart, 2013). 
 
Abbreviations   
Step length 
 
The distance that one part of the foot 
travels in front of the same part of the 
other foot during each step (Baker and 
Hart, 2013). 
Stride length The distance that one part of the foot 
travels between the same instant in two 




A measure of the mediolateral separation 
of the feet (Baker and Hart, 2013). 
Double support  The phase where both feet are in contact 
with the floor (Baker and Hart, 2013). 
Velocity 
 
The distance travelled in a given time. It is 
determined by the cadence and step/stride 
length (Baker and Hart, 2013). 
Stride time  
 
This is the duration of one gait cycle 
(Baker and Hart, 2013). 
Cadence Number of steps per minute (Baker and 
Hart, 2013). 
AD   Alzheimer’s disease 
 
SCI    Subjective cognitive impairment  
 
MCI    
 
Mild cognitive impairment 
MMSE  Minimal mental state examination  
 
SL   Step length 






According to the Norwegian Directorate of Health approximately 70 000 people in Norway are 
suffering from some form of dementia (Helsedirektoratet, 2011), and it is likely that more and 
more will develop this condition due to an increasing proportion of elderly (Helsedirektoratet, 
2011). Dementia is defined as a syndrome of acquired persistent intellectual impairment 
characterized by deterioration in at least three of the following domains; memory, language, 
visuospatial skills, personality or behaviour, and manipulation of acquired knowledge (Kowall 
and Budson, 2011). Alzheimer’s disease (AD) is the most common form of dementia, 
responsible for more than half of the cases (Gras et al., 2015, Jacobsen and Toverud, 2009, 
Weller and Dickson, 2012). Subjective cognitive impairment (SCI) and mild cognitive 
impairment (MCI) are conditions describing early stages of dementia, and can persist for 
several years (Jessen et al., 2014). Previous studies have shown that patients with MCI and AD 
have reduced motor function compared with healthy elderly subjects (Aggarwal et al., 2006, 
Goldman et al., 1999, Kluger et al., 2008). The loss of independence and safe mobility due to 
balance and gait dysfunction in AD patients has been recognized for years (Gras et al., 2015), 
and reduced walking speed has been observed among patients with both MCI and AD 
(Aggarwal et al., 2006, Goldman et al., 1999, Gras et al., 2015). However, few studies have 
investigated motor function in people with SCI. 
 
Gait speed has long been acknowledged as an important aspect of gait and is often used as an 
objective measure of functional mobility in both clinical settings and research (Peters et al., 
2013). Furthermore, gait speed is a predictor of life length (Hardy et al., 2007), future 
functional decline, risk of falling (Peters et al., 2013), health costs and health status (Purser et 
al., 2005). There is sufficient evidence to consider gait speed as a strong predictor of adverse 
outcomes in community dwelling elderly (Abellan van Kan et al., 2009).  
 
The step length/cadence relationship, also known as the walk ratio (WR) (Sekiya et al., 1996), 
is yet to be studied in individuals with cognitive impairment. WR is calculated by dividing the 
length of one step by the cadence (number of steps per minute). As an example, imagine a 




assume that the walking strategy would include short and fast steps as compensation to 
increase stability, yielding a low WR. In contrast, normal step length and cadence would be 
preferred in a well-lit space or on a dry surface. Interestingly, when adjusted for stature, WR is 
almost independent of walking speed, age and sex and is generally constant in healthy elderly 
(Egerton et al., 2011, Rota et al., 2011). Rota et al. (2011) reported that the WR tells us 
something about the quality of how we walk, as opposed to gait speed, which may be affected 
by factors such as motivation and physical condition. They argued that WR is a more specific 
variable than gait speed, and suggested that WR can be a parameter for comparing health and 
disease. A lower value or change in WR could either predict disease or provide an indication of 
improvement or of functional decline.  
 
WR is seldom reported in gait studies, but spatiotemporal characteristics like step length and 
cadence are frequently reported and lend themselves to calculate WR. Considering that studies 
have shown that patients with MCI and AD have impaired gait function (Aggarwal et al., 2006, 
Goldman et al., 1999, Kluger et al., 2008), examining WR in a population who has 
subsequently shown to have reduced gait function is intriguing. Hence, it is of interest to do 1) 
a literature search investigating spatiotemporal characteristics to see if there is an association 
between the degree of dementia and WR, and 2) a cross-sectional trial in a clinical setting to 
evaluate the WR in an early, pre-dementia stage (SCI and MCI) population. This is of 
relevance when we know that the development of AD initiates long before patients become 
symptomatic (Egerton et al., 2011), and physical function may decrease simultaneously or 
before the development of cognitive problems (Tangen et al., 2014). WR may possibly be used 
to predict disease even in an early stage of cognitive impairment. Because the WR is more or 
less independent of gait speed it could be a more sensitive and specific measure of gait 






1.2 Aims of the thesis 
The first aim of this thesis is to explore the presumed association between the minimal mental 
state examination-score and walk ratio by reviewing relevant literature where either WR or 
spatiotemporal gait parameters are reported in populations of cognitively impaired elderly 
persons. The second aim is to investigate if walk ratio can predict group membership between 
patients with SCI, MCI and healthy controls in a clinical setting. This may also give an 






2.1 Dementia  
Dementia is defined as a syndrome of acquired persistent intellectual impairment characterized 
by deterioration in at least three of the following domains: memory, language, visuospatial 
skills, personality or behaviour, and manipulation of acquired knowledge (Kowall and Budson, 
2011). Brodal (2007) explains dementia as an acquired global reduction of intellectual abilities, 
reason and personality, without changes in the state of consciousness. At late stages of 
dementia, the patients are no longer oriented for time, place or situation (Jacobsen and 
Toverud, 2009). Dementia rarely appears before the age of 60, but the rate increases with age, 
especially after the age of 75. It is estimated that one third of people over 85 years of age have 
signs of dementia (Jacobsen and Toverud, 2009) and it is one of the leading causes of disability 
in the elderly population (Tangen et al., 2014). Dementia can have multiple causes, but a 
common factor is a widespread degeneration of the cortical synaptic connection (Brodal, 
2007). Dementia can occur after repeated infarcts that eventually may destroy brain tissue. 
These infarcts in the white matter lead to what is known as vascular cognitive impairment. 
Most cases of dementia, however, are caused by neurodegenerative diseases that gradually 
leads to loss of neurons (Brodal, 2007).  
 
2.1.1 Alzheimer’s disease  
The majority of patients with dementia have Alzheimer’s disease (AD), which is a progressive 
neurodegenerative disease without a known cause or treatment (Gras et al., 2015, Jacobsen and 
Toverud, 2009). It usually starts to evolve before the age of 60 (Brodal, 2007). The symptoms 
are associated with psychiatric, cognitive and physical impairments, leading to loss of 
independence, major healthcare costs and a heavy burden on relatives (Tangen et al., 2014). 
The involvement of entorhinal cortex, the hippocampus and the frontal and parietal associative 
cortical areas is well established (Suva et al., 1999), whereas the primary motor cortex is 
generally accepted to be less involved or even spared (Brodal, 2007, Suva et al., 1999). 
However, a study performed by Suva et al. (1999) found that the primary motor cortex was 
significantly involved in AD and suggested the presence of motor dysfunction in late or 




2.1.2 Mild cognitive impairment  
MCI is a term describing an individual who has some degree of cognitive impairment, but does 
not meet the criteria for dementia. Although it is regarded a common condition that occurs 
between normal aging and dementia, there is a lack of consensus about its definition (Aggarwal 
et al., 2006). The core clinical criteria for MCI are personal concern regarding decline in 
cognitive function preferably confirmed by an informant, objective impairment in one or more 
cognitive domains, normal general cognitive function and independence in functional abilities 
(Albert et al., 2011). The literature indicates that people with MCI score more poorly on 
neuropsychological and motor tests and are at a higher risk for future dementia development 
compared with cognitively unimpaired (Kluger et al., 2008). MCI is associated with an 
increased risk of developing AD, but far from all patients with MCI develop AD (Aggarwal et 
al., 2006).  
 
2.1.3 Subjective cognitive impairment  
SCI may be the earliest point of clinical AD symptomatology (Fonseca et al., 2015). SCI 
describes the occurrence of a person reporting or admitting to cognitive function that they feel 
is impaired (Stewart, 2012). The terminology of this stage varies, but SCI is an increasingly 
accepted term (Fonseca et al., 2015). The criteria for SCI are experienced persistent decline in 
cognitive function in comparison with previously normal status, in addition to normal age-, 
gender, and education-adjusted performance on standardized cognitive tests. In addition, the 
perceived decline cannot be explained by psychiatric or neurologic disease, medial disorder, 
medication or substance use (Jessen et al., 2014). Fonseca et al. (2015) describe SCI as a 
disease stage where possible neuropathological damage is offset by compensatory mechanisms. 
It is a risk factor for further cognitive decline to both MCI and AD (Jessen et al., 2014). SCI 
has been a controversial entity since it first was considered as a research topic. Clearly, 
impaired cognitive function can have a heterogeneous origin, like depression or other mental 
disorders, and many people reporting memory problems have no observable or objectively 
measured deficits (Stewart, 2012). However, empirically it is likely that people developing 
dementia at some point notice their cognitive impairments, without seeking help. And even 
though SCI is a condition that is difficult to define, there are very few other ways in which 






Locomotion is characterized by three essential requirements: progression, postural control and 
adaption (Shumway-Cook and Woollacott, 2012). Progression is ensured through patterns that 
produce and coordinate rhythmic patterns of muscle activation that successfully move the 
body. Postural control is the ability to establish and maintain appropriate posture for 
locomotion and dynamic stability. The ability to adapt gait is important for meeting the goals 
of the individual and the demands of the environment. These requirements must be met with 
strategies that are both energy-efficient and effective in minimizing stress to the body 
(Shumway-Cook and Woollacott, 2012). 
 
Gait is a complex mode of behaviour involving the entire body. Navigation through complex 
environments requires the use of sensory inputs to assist in the control and adaption of gait 
(Shumway-Cook and Woollacott, 2012). Gait includes stance and swing phases. During stance 
phase, we need to generate forces against the support surface. The goals of the swing phase 
include advancement of the swing leg and repositioning of the limb in preparation for weight 
acceptance. In addition, strategies used to accomplish progression and postural control must be 
flexible to accommodate changes in speed and direction or alteration in the surface The stance 
phase starts when the foot strikes the ground, and the swing phase starts when the foot leaves 
the ground. At their usual pace, an adult typically keeps each leg 60 percent of the cycle 
duration in the stance, and 40 percent in swing. Approximately, the first and last 10 percent of 
the stance phase are spent in double support (Shumway-Cook and Woollacott, 2012). 
 
Kinematic studies suggest that all normal subjects use the same movement strategy for 
walking. However, studies describing muscles and forces associated with gait suggest that 
there are a tremendous variability in the way the strategy is achieved (Shumway-Cook and 







2.3 Walk ratio  
Gait speed is the product of step length (SL) and cadence and we can use an infinite 
combination of these variables when walking (Sekiya et al., 1996). Usually, WR remains 
constant at a value around 0.65 (± 0.08) cm/(step/min) when normalized for height in an adult 
healthy population (Sekiya et al., 1996). WR tells us more about the quality of how we walk, 
while gait speed is a measure of performance. A low ratio tells us that an individual takes small 
steps and has a high step frequency. A higher ratio tells us that the individual takes longer 
steps, holds a lower frequency or both. Curiously, Rota et al. (2011) points out that during 
indoor short distance walking, the ratio between step length and cadence remains constant, 
once both are normalized for height. Other gait parameters, kinematic or kinetic, change with 
different gait speed but the WR maintains independent of speed except at extremely slow or 
fast speed (Sekiya and Nagasaki, 1998). In addition, WR has shown to be independent of age 
and sex (Egerton et al., 2011, Sekiya et al., 1996) in healthy populations. Sekiya et al. (1996) 
suggest that the WR can be an index for describing temporal and spatial coordination or gait 
pattern at any given speed. Since the WR remains constant over a wide range of walking speed, 
it suggests that human walking is extremely coordinated as to keep the ratio constant. It also 
seems like the preferential WR is the one that reduces energy cost (Cavagna and Franzetti, 
1986, Sekiya et al., 1996). Further, it is suggested that a deviation from the normal WR during 
free walking may indicate or reveal some form of abnormal walking patterns (Sekiya and 
Nagasaki, 1998). Studies have also shown that smaller steps and a higher cadence might 
predict falls in elderly (Barak et al., 2006, Callisaya et al., 2012)  
 
2.4 Gait function with aging and cognitive impairment 
With increasing age follows several structural and biochemical alterations in the brain (Brodal, 
2007). Both mental and motor processes slow down, especially for task with high demand of 
speed and when learning new tasks. Highly automated intellectual and also motor skills (such 
as walking), are less affected by age (Brodal, 2007). However, both gait and balance are often 
impaired in older adults. They are major contributors to falls among this population and usually 
have a complex origin (Salzman, 2010). A meta-analysis (Bohannon and Williams Andrews, 
2011) found that gait speed varies as a function of age and sex. They also found that the 
velocity decreases each decade after 60 to 69 years. Changes in gait may have different 




found that in neurologically healthy elderly people, the velocity of gait and length of stride was 
reduced between 17-20 percent, compared to young adults (Elble et al., 1992). In addition, 
studies have shown that elderly who fall have abnormal walking patterns. Both shorter stride 
length and lower velocity seems to be present in fallers compared with non-fallers in an elderly 
population (Wolfson et al., 1990). Salzman (2010) writes that characteristics of gait that 
changes with age is increased stance width, increased time in double support, bent posture, and 
less vigorous force developed at the moment of push off. This may represent adaptions to 
alterations in sensory or motor systems to give a more stable gait pattern. Twenty percent of 
older adults actually maintain normal gait into very old age (Salzman, 2010). Thus, Salzman 
(2010) argue that these kinds of gait impairments are caused by one or more underlying 
conditions.  
 
Studies report that dementia in itself is a risk factor for falling in elderly populations (Persad et 
al., 2008, Shaw, 2002, van Doorn et al., 2003) and that patients with dementia have poorer 
prognosis when falls occurs (Shaw, 2002). In AD, gait disorders are common, with prevalence 
increasing with the progression of AD. It has been suggested that AD related gait disorders are 
not only an accompanying result of the disease, but also a specific sign of AD-related cognitive 
decline (Annweiler et al., 2012). Annweiler et al. (2012) suggest that studying AD-related gait 
disorders is attractive in the sense that it can predict adverse outcomes such as falls, loss of 
independency, institutionalization, hospitalization and death. Gait disorder may also even 
appear before memory impairments in patients with AD. Thus, gait disorders might be a 
supplement for early diagnosing AD. AD related gait disorders have been related to the 
impairment of higher levels of gait control at subcortical and cortical levels. It remains unclear 
which brain structure and related lesions are specifically involved and could explain the gait 
impairments. In other types of dementia like Parkinsonism, that links with basal ganglia 
disorders, gait disorders are well described and understood (Annweiler et al., 2012).  
 
Gait disorders are also reported in MCI, owing to probable changes in higher levels of motor 
control (Annweiler et al., 2013). It has been reported that MCI patients have slower gait speed 
(Montero-Odasso et al., 2012, Verghese et al., 2008), but also lower gait stability (Beauchet et 
al., 2013). It has been suggested that cognitive decline can lead to gait disorders independent of 
decline in muscle strength, tone or osteoarticular functions that may accompany aging 
(Annweiler et al., 2013). Annweiler et al. (2013) showed that abnormal metabolite ratios in the 




with poor gait performance while single and dual tasking. They argued that this underscored 
the possible involvement of decreased neuronal function in the primary motor cortex causing 
gait disorders observed in MCI (Annweiler et al., 2013). To the best of our knowledge, no 







This is a twofold study consisting of a literature review investigating the association between 
WR and the degree of cognitive impairment, and a cross- sectional trial in a clinical setting 
investigating gait impairment in patients with cognitive impairment compared to healthy 
controls.  
3.1 Part 1 – Literature review  
3.1.1 Study design 
Because no studies have explored WR in a population with cognitive impairment an 
exploratory literature search for studies examining gait function in this population was 
conducted. The results were narrowed down to studies containing the variables needed to 
calculate WR of the participants in the studies.  
3.1.2 Search strategy  
The literature search for this thesis was performed through PubMed, PEDro, AMED, 
Cochrane, Embase, MEDLINE and PsycINFO with assistance from an experienced librarian 
(last search date: 13
th
 of March 2015). The search terms were as follows: (step length OR stride 
length) AND (cadence OR step frequency OR gait OR walk speed OR velocity OR walk ratio) 
AND (dement* OR Alzheimer* OR mild cognitive impairment). The search terms were used 
as mesh terms or text words and were adjusted for the different databases. The full search 
strategy is available in the appendix. Unpublished studies and abstracts were not included. 
Languages were restricted to English or Norwegian due to time resources.  Article references 
were screened for potentially relevant studies, resulting in 16 additional articles. The PRISMA 
2009 Flow Diagram (Moher et al., 2009) was used to illustrate the selection process of the 
studies.  
3.1.3 Inclusion and exclusion criteria 
The study population had to be patients with cognitive impairment for which the diagnostic 
process was accounted for. The studies had to include the gait variables step length, cadence, 
WR or the possibility to calculate WR for the different groups of participants. In addition, to 
compare the degree of cognitive impairment between studies the Minimal Mental state 
examination (MMSE)-score had to be included, a short examination focusing on the cognitive 




comparable, it had to be stated whether the studies measured «steady state» walking, which is 
walking without the acceleration or deceleration phase. Only the studies measuring steady state 
walking were included in the study. The gait assessment had to be done on a level floor and not 
for example on a treadmill. The participants also had to be free of neurological or orthopaedic 
diseases that could affect the gait assessment. Study design was not considered as an exclusion 
criteria, because different designs could be eligible for inclusion.   
3.1.4 Variables and data collection 
Data was collected from the included studies. Some of the studies had several groups like 
control groups and interventions groups, resulting in a higher number of groups than the 
number of included studies. Variables extracted from the studies were baseline MMSE-score, 
age and WR from each group, thus the mean of each group was used in further analysis. 
Follow up data from longitudinal cohorts studies without intervention was included. Healthy 
control groups were included as long as they met the criteria for inclusion. 
3.1.5 Analysis  
Statistics was performed in Microsoft Excel for Windows 8 and in the Statistics Package for 
Social Science (SPSS) 22.0 for Windows. The following baseline variables were computed: 
MMSE-scores, WR and age. We retrieved and calculated WR from cadence and step length in 
studies that did not explicitly include WR as a variable. To see if the results were affected by 
sample size, the variables were weighted according to the number of participants, and weighted 
group means were compared with the original group means. The weighted group means did not 
differ from the original means, thus the original means were used in further analysis. Using 
bootstrapping procedures in the correlations and regression analysis confirmed that departures 
from normality did not affect the results. Therefore, only parametric procedures without 
bootstrapping are presented for correlation and regression. For correlations and sample 
characteristics, Pearson’s R was used. For explained variance, linear regression was conducted. 
The independent variables were also checked for multicollinearity. The independent t-test was 
used to compare means between controls and people with cognitive impairment. The 





3.2 Part 2 – Cross-sectional study 
3.2.1 Study design  
A cross-sectional design was used in order to assess WR in populations with SCI and MCI and 
compare them to healthy controls.  
3.2.2 Study population 
The study population included patients diagnosed with SCI or MCI in addition to a healthy 
control group. They were diagnosed and recruited through the dementia-disease initiation 
project. The participants were diagnosed by a geriatrician according to the recommendation 
from the National Institute on Aging-Alzheimer’s association (Albert et al., 2011). Thus, the 
patients completed a thorough diagnostic process before entering the study. Eligible subjects 
were screened for cognitive function with the following test battery; Trail making A & B 
(Reitan and Wolfson, 1993), FAS (Benton, 1989), The Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) (Fillenbaum et al., 2008), Minimal mental state examination 
(MMSE) (Folstein et al., 1975), Clock-drawing (Shulman, 2000). To be diagnosed with MCI 
the participants had to score below the normality cut-off in at least one of the tests. The 
normality cut-off used for MMSE was ≥28 points and ≥1.5 standard deviations for the 
remaining tests. The inclusion criteria for the symptomatic groups in the dementia-disease 
initiation project was recently acquired symptoms of cognitive impairment, between the age 
40-85 and having Norwegian, Swedish or Danish as their first language. The control group 
contained participants without cognitive symptoms. Exclusion criteria were brain injury, 
including stroke, known dementia, severe psychiatric disease, intellectual disability, severe 
somatic disease that can affect cognitive function or medical treatment that could affect 
cognitive function. In addition, exclusion criteria for this cross-sectional study were 
neurological disease, orthopaedic injuries or operations that could cause gait impairment or 
inability to walk 10 meters without aid.  
3.2.3 Power  
There are no studies examining WR in a population with cognitive impairment, thus estimating 
the sample size needed from previous studies was not possible. In the literature review, the 
mean numbers of participants per groups were 20. Since these were studies investigating gait 
variables in populations with cognitive impairment, this sample size was used as an indicator 




3.2.4 Data collection  
The 10-meter walk test  
The 10-meter walk test is commonly used for the assessment of walking speed and has high 
test-retest and interrater reliability (Peters et al., 2013). It requires a 20 meter walking path 
including 5 meters for acceleration and deceleration at either side (Peters et al., 2013), 
illustrated in Figure 1. This test needs little equipment and is easy to perform. A line was 
drawn at the start and at the end of the walkway. The participants were told not to stop before 
reaching the end line. First, they were instructed to walk at their preferred speed («your usual 
pace»), second, they were asked to walk fast, («as fast as you can without running or losing 
your balance») and third, slow («waiting for the bus»).  
 
The test measured steady state walking with dynamic start. The observer started the stopwatch 
as the participant passed a small, discrete, 5-meter mark on the floor, and stopped at a similar 
10-meter mark, so that only the mid 10 meters walking was timed, thus excluding the 
acceleration and decelerations phases. The number of steps used to complete 10 meters was 
counted by the observer. Data of two consecutive trails were collected and the average was 
used in further analysis.  
  




Other variables  
Other variables collected from the participants were body height without shoes, gender and 
age. 
3.2.5 Analysis  
Gait variables 
The gait variables needed to calculate WR were step length and cadence. These were 
calculated from data collected from the 10-meter walk test.  
 
Velocity (m/s) = 10 meters / time (seconds)   
Step length (cm) = 1000 cm / number of steps   
Meters walked pr. minute = walking speed x 60 seconds 
Cadence: steps pr. min = meters walked pr. minute / step length 
WR = Step length / cadence  
Adjustment for height 
Because gait parameters are dependent on stature, they need to be adjusted for size when 
making comparisons between subjects. It is assumed that step length is proportional to leg 
length and that cadence follows pendulum laws. The equation for the frequency (f) of a simple 
pendulum is: 
 
f = [√(g/L)]/(2*3.14) (Store norske leksikon, 2009) 
 
The equation demonstrates that f is proportional to the inverse of the square root of the length 
(L) of the pendulum since acceleration due to gravity (g) is a constant. If cadence follows 
pendulum laws, cadence is therefore proportional to the inverse of the square root of leg length. 
If leg length is assumed proportional to body height, cadence is also proportional to the inverse 
of the square root of body height. In this study, adjustment for height were done in accordance 
with the recommendations of Sekiya et al. (1996) who followed the above principles when 
adjusting gait parameters to average body height. The following formulas were used:  
 
Adjusted step length: SLn = (step length/height) *(average height)  
Adjusted cadence: CADn = cadence*(height/average height) 
½
 




Adjusted walk ratio = SLn/CADn 
Statistical analysis  
Statistics was performed in Microsoft Excel for Windows 8 and the Statistics Package for 
Social Science (SPSS) 22.0 for Windows. The following variables were computed: Step length, 
cadence, WR and velocity for the three gait speeds for the three different groups. The data were 
normally distributed. Pearson’s R was used for correlation. One-way Multinomial logistic 
regression was used to compute odds ratios (OR) for the different groups, making it possible to 
adjust for other variables. To measure the overall differences between groups, analysis of 
variance (ANOVA) was used. Further, Dunnet’s post hoc test was used to compare the MCI 
and SCI group to the control group. The significance threshold was set at 0.05.  
 
3.3 Ethical considerations  
The participants in this study were recruited from the dementia-disease initiation project. This 
project protocol was approved by the regional ethic committee (appendix). This thesis is a 
subproject to the original dementia-disease initiation project, approved by the leader of the 
project, Dag Aarsland (appendix). The participants volunteered and signed a written consent. 
They were informed that they could withdraw from the study at any time, without having to 
explain why. The 10-meter walk test was considered as minimal invasive, and efforts were 
made to make sure no harm would come to the patient during the assessment. The assessment 
was supervised by a physiotherapist. Information about the participant’s name and 
identification number was always kept separate. Other information about the participants was 
always kept on paper and locked in.  
 
3.4 Resources, equipment and expenses  
There were few expenses related to this thesis. The dementia-disease project refunded the 
participants travel expenses. The equipment needed was tape, a stopwatch, measurement band 
and a well-lit hallway. The author has a 10 percent post at the dementia-disease project to help 











4.1 Part 1 - The literature review  
 
Figure 2 shows an overview of the study selection process. The initial database search yielded 
483 studies. Removing duplicates, a total of 273 studies were left for screening of title and 
abstract. Additionally, 16 studies were added through references from studies achieved from 
the literature search. Last, 117 studies were further screened in full text, yielding a total of 16 
studies for inclusion as displayed in Table 2. The ranges of the meters walked between the 
included studies were 3.7 meters – 10.0 meters. One of the studies measured fast walking 

































Table 1. Included studies from the literature review 







A longitudinal study of gait function and 
characteristics of gait disturbance in 
individuals with Alzheimer's disease 
Cedervall, Y., 
Halvorsen, K., & 
Aberg, A. C. 




21 Mild Alzheimer's 
disease  
25,0 72 1,14 110,3 62 0,56 
      21 Mild Alzheimer's 
disease a) 
22,0 73 1,10 110,0 60 0,55 
          21 Mild Alzheimer's 
disease b) 
21,0 74 1,01 106,3 57 0,54 
Multimodal exercise intervention 
improves frontal cognitive functions and 
gait in Alzheimer's disease: A controlled 
trial  
de Melo Coelho, F. G., 
Andrade, L. P., 
Pedroso, R. V., Santos-
Galduroz, R. F., Gobbi, 
S., Costa, J. L. R., & 
Gobbi, L. T. B. 




14 Mild and Moderate 
Alzheimer's disease 
19,5 78 0,79 103,0 46 0,45 
          13 Mild and Moderate 
Alzheimer's disease 
19,0 77 0,71 99,1 43 0,43 
Gait and risk of falls associated with 
frontal cognitive functions at different 
stages of Alzheimer's disease  
de Melo Coelho, F. G., 
Stella, F., de Andrade, 
L. P., Barbieri, F. A., 
Santos-Galduroz, R. F., 
Gobbi, S., Costa, J. L. 







12 Mild Alzheimer's 
disease 
22,0 76 0,78 99,6 47 0,47 
          11 Moderate 
Alzheimer's disease  
16,2 80 0,67 98,1 41 0,42 
Effects of multicomponent exercise on 
spatial-temporal gait parameters among 
the elderly with amnestic mild cognitive 
impairment (aMCI): Preliminary results 
from a randomized controlled trial 
(RTC) 
Doi, T., Makizako, H., 
Shimada, H., Yoshida, 
D., Tsutsumimoto, K., 
Sawa, R., Misu, S. & 
Suzuki, T 
2012 Archives of 
Gerontology and 




25 Amnestic mild 
cognitive 
impairment  
26,8 75 1,10 115,8 57 0,49 
          25 Amnestic mild 
cognitive 
impairment  
26,6 77 1,10 117,9 56 0,48 
Balance and Gait of Adults With Very 
Mild Alzheimer Disease  
Gras, L. Z.,Kanaan, S. 
F., McDowd, J. M., 
Colgrove, Y. M., 
Burns, J. & Pohl, P. S. 





13 Normal controls 29,0 73 1,49 116,1 77 0,66 
          13 Very mild 
Alzheimer's disease 











Gait and cognition: The relationship 
between gait stability and variability 
with executive function in persons with 
and without dementia 
Ijmker, T., & Lamoth, 
C. J. 




14 Older controls  28,5 80 1,40 112,1 61 0,54 
      12 Younger controls  29,1 64 1,19 112,4 64 0,57 
          15 Alzheimer's disease 
and fronto temporal 
dementia 
19,6 82 0,67 100,8 40 0,40 
Quantitative gait analysis under dual-
task in older people with mild cognitive 
impairment 
Montero-Odasso, M., 
Casas, A., Hansen, K. 
T., Bilski, P., 
Gutmanis, I., Wells, J. 
L., & Borrie, M. J. 




Reliability study 13 Mild cognitive 
impairment  
28,0 77 1,19 108,4 65,88 0,61 
Dual-Task complexity Affects Gait in 
People With Mild Cognitive Impairment: 
The Interplay Between Gait Variability, 
Dual Tasking, and Risk of Falls 
Montero-Odasso, M., 
Muir, S. W., & 
Speechley, M. 
2012 Arch Phys Med 
Rehabil Vol 93 
Cross-sectional 
study 
26 Normal controls  29,5 72 1,34 115,6 70 0,61 
          43 Mild cognitive 
impairment  
27,8 75 1,11 107,6 62 0,58 
Gait assessment in mild cognitive 
impairment and Alzheimer's disease: The 
effect of dual-task challenges across the 
cognitive spectrum 
Muir, S. W., 
Speechley, M., Wells, 
J., Borrie, M., Gopaul, 
K., & Montero-Odasso, 
M. 




22 Normal controls  29,5 71 1,36 114,6 71 0,62 
      29 Mild cognitive 
impairment  
27,5 74 1,16 111,4 62 0,56 
          23 Alzheimer's disease  24,2 78 1,11 108,7 61 0,56 
Spatial and temporal gait parameters in 
Alzheimer's disease and aging  
Nadkarni, N., Mawji, 
E., McIlroy, W., & 
Black, S. 




34 Normal controls  29,0 74 1,19 109,0 65 0,60 
         40 Alzheimer's disease 25,0 74 0,99 101,0 59 0,58 
Gait and Subcortical Hypertensities in 
Mild Alzheimer's Disease and Aging 
Nadkarni, N. K., 
McIlroy, W. E., Mawji, 
E., & Black, S. E.  





21 Alzheimer's disease 
+ c) 
25,0 77 0,96 102,0 56 0,55 
      21 Alzheimer's 
disease- 
24,0 71 1,02 101,0 61,5 0,61 
      15 Normal Controls + 28,0 76 1,11 106,0 62 0,58 











Improvements in gait characteristics 
after intensive resistance and functional 
training in people with dementia: a 
randomized controlled trial  
Schwenk, M., 
Zieschang, T., Englert, 
S., Grewal, G., Najafi, 
B., & Hauer, K. 
2014 BMC Geriatrics 
2014, 14:73 
Randomized 
controlled trial  
20 Mild to moderate 
dementia 
21,0 80 1,33 137,1 58,29 0,43 
          29 Mild to moderate 
dementia 
21,7 82 1,29 134,5 57,66 0,43 
Test-retest reliability of spatial and 
temporal gait parameters of people with 
Alzheimer's disease  
Wittwer, J., Webster, 
K., Andrews, P., & 
Menz, H.  
2008 Gait & Posture 28 
(2008) 392–396 
Reliability study 20 Alzheimer's disease  22,0 81 1,06 106,5 59,7 0,56 
Reproducibility of gait variability 
measures in people with Alzheimer's 
disease 
Wittwer, J. E., 
Webster, K. E., & Hill, 
K. 
2013 Gait & Posture 
2013, 38:3, s. 507-
10 
Reliability study 16 Alzheimer's disease 21,0 81 1,00 104,7 57,35 0,55 
The effects of a concurrent motor task on 
walking in Alzheimer's disease 
Wittwer, J. E., 
Webster, K. E., & Hill, 
K. 




30 Alzheimer's disease  20,6 80 1,12 109,6 60,7 0,55 
             
A longitudinal study of measures of 
walking in people with Alzheimer's 
disease 
Wittwer, J. E., 
Webster, K. E., & 
Menz, H. B. 




11 Mild Alzheimer's 
disease   
24,5 80 1,12 105,9 64 0,60 
      8 Moderate 
Alzheimer's disease  
16,6 78 0,93 101,8 54 0,53 
          19 Normal controls  28,9 80 1,18 111,0 64 0,58 
a) 1-year follow-up (no intervention between)  
b) 2-year follow-up (no intervention between) 










4.1.2 Association between walk ratio and MMSE   
Descriptive statistics of the literature review are displayed in Table 2. Since some studies 
stratified their participants into different groups of cognitive impairment, or had intervention 
and control groups, the total number of groups was 34. The total amount of participants in 
these studies was 688. There was 25 groups with cognitive impairment with a total of 515 
participants, leaving 9 groups of healthy controls with a total of 173 participants. Follow-up 
data was used from one of the studies (Cedervall et al., 2014), meaning data from the same 
participants (n=21) were used twice.  
 
Table 2. Descriptive statistics of WR, MMSE and age from the literature review 
 
  Mean  SD 
Total group 
(n = 34) 
WR 0.54 0.07 
 MMSE 24.4 3.9 
 Age 75.9 4.1 
Cognitive 
impairment  
(n = 25) 
WR 0.52 0.07 
 MMSE 22.9 3.3 
 Age 77.0 3.3 
Healthy controls  
(n = 9) 
WR 0.60 0.03 
 MMSE 28.9 0.5 
 Age  73.1 5.0 
 
WR: Walk ratio 
MMSE: Minimal mental state examination 











Table 3. Correlation between WR, MMSE and age from the literature review 
  WR MMSE  Age 
Total group 
(n = 34) 
WR   1.00   0.69* - 0.54* 
 MMSE   0.69*   1.00 - 0.55* 
 Age - 0.55* - 0.55*   1.00 
Cognitive 
impairment  
(n = 25) 
WR   1.00   0.58* - 0.52* 
 MMSE   0.58*   1.00  -0.50* 
 Age - 0.52* - 0.50*   1.00 
Healthy controls  
(n = 9) 
WR    1.00   0.42 - 0.32 
 MMSE    0.42   1.00 - 0.52 
 Age  - 0.32 - 0.52   1.00 
Data were analysed using Pearsons’s r correlation coefficient 
* Correlation is significant at the < 0.05 level 
 
WR: Walk ratio 
MMSE: minimal mental state examination  
 
 
The correlations between the variables are displayed in Table 3. The correlations between WR 
and MMSE for the total group was high (r = 0.69, P < 0.001). The explained variance between 
WR and MMSE was R
2
=0.48. A scatterplot between WR and MMSE is displayed in Figure 3. 
There was an inverse correlation between WR and age for the total group (r = -0.55, P= 0.001). 
The explained variance between WR and age was R
2














Figure 3. Scatterplot of the relationship between WR and MMSE 
WR: Walk ratio (step length / cadence) 









Figure 4. Scatterplot of the relationship between WR and Age 
WR: Walk Ratio (step length / cadence)  
 
Using linear regression between WR, MMSE and age, with WR as the dependent variable, 
resulted in R
2 
= 0.52. Across the individual independent variables, only MMSE had a 
significant contribution to this model (P < 0. 001) as opposed to age (P = 0.12). There was no 
multicollinearity between the independent variables MMSE and age.  
 
Differences between participants with cognitive impairment and healthy controls 
Within the cognitive impairment group, the correlation between WR and MMSE was r = 0.58 
(P = 0.03), which was lower than the total group correlation. The explained variance between 
WR and MMSE was R
2 
= 0.33.  WR was linearly regressed over MMSE and age, with WR as 
the dependent variable, resulting in R
2 
= 0.4. The independent t-test showed that the control 
group had a statistical significantly higher WR (P < 0.001) and MMSE-score (P < 0.001) 
compared to the cognitive impairment group. The participants from the control group had 
significant lower age (P = 0.01) than the participants in the cognitive impaired group. 
However, the linear regression within the cognitive impaired group showed that only MMSE 
had a significant contribution to the model (P = 0.04) as opposed to age (P = 0.12). In addition, 




4.2 Part 2 – Cross sectional study  
In total, 75 participants were screened for eligibility. Five participants were excluded due to 
orthopaedic or neurological disorders, resulting in 70 eligible participants. These were 
classified as controls (n=23), SCI (n=28) and MCI (n=19). The enrolled controls were 8 men 
and 14 women (mean age 60.0 ± 8.0, mean MMSE 29.7±0.8). The SCI groups consisted of 12 
men and 16 women (mean age 63.1 ± 9.1, mean MMSE 29.6±0.6). Finally, the MCI groups 
were 12 men and 7 women (mean age 68.5 ± 8.6, mean MMSE 27.8±2.0). Descriptive 
statistics of the different measures of gait performance are presented in Table 4.  
 
Table 4. Descriptive statistic of the different gait variables from the cross-sectional trial 

































0.66 0.11 0.59 0.07 0.56 0.09 
Velocity (cm/s) 105.4 22.9 155.2 20.4 205.0 21.4 
Step length (cm) 63.5 5.9 73.6 6.3 82.1 6.5 
Cadence (steps pr. min) 98.8 16.6 126.4 12.5 150.1 16.4 








0.64 0.11 0.59 0.07 0.55 0.10 
Velocity (cm/s) 96.1 18.7 140.8 20.8 195.4 29.2 
Step length (cm) 60.1 6.0 70.1 6.5 79.5 6.3 
Cadence (steps pr. min) 95.8 15.8 120.2 12.3 147.6 20.1 








0.63 0.17 0.60 0.07 0.58 0.07 
Velocity (cm/s) 102.2 16.8 135.8 24.8 180.8 27.2 
Step length (cm) 61.3 8.7 69.7 7.7 78.8 6.8 





SCI: Subjective cognitive impairment 
MCI: Mild cognitive impairment 
WR: Walk ratio  






There were statistical differences between groups in velocity, determined by the one-way 
ANOVA at preferred gait speed (P = 0.01) and at fast gait speed (P = 0.02). A post hoc 
Dunnet’s test showed that there were statistical significant differences between MCI and 
controls (P = 0.005) and between SCI and controls (P = 0.02) in velocity at preferred gait 
speed. In addition, there were statistical significant differences between MCI and controls (P = 
0.002) at fast gait speed. None of the other gait variables differed significantly between groups. 




Figure 5. Difference in mean walk ratio at preferred gait speed 
Error bars with 95% confidence intervals  
WR: Walk ratio 
SCI: Subjective cognitive impairment 






Figure 6. Difference in mean velocity at preferred gait speed 
Error bars with 95% confidence intervals 
SCI: Subjective cognitive impairment 
MCI: Mild cognitive impairment  
 
 
A multinomial logistic regression analysis was conducted with diagnostic group (0 = control, 1 
= SCI, 2 = MCI) as the dependent variable, the different gait variables as the independent 
variables and age and gender as independent covariates. When adjusted for age and gender the 
Multinomial logistic regression analysis showed that velocity at preferred speed and had a 
statistical significance decrease in odds ratio for predicting group membership for both SCI 
(OR = 0.967 95% CI 0.938 to 0.997, P = 0.03) and MCI (OR = 0.963, 95% CI 0.930 to 
0.996, P = 0.03). Further, the analysis showed that velocity at fast speed could predict MCI 






WR did not significantly predict group membership for SCI or MCI at any speed, neither did 
step length nor cadence. Higher age predicted MCI group membership (OR = 1.07 95% CI 
1.01 to 1.21, P = 0.02). The results are displayed in table 6. and 7. To look for associations 
between age and velocity in the MCI group a partial correlation was conducted. There was no 
significant correlation between age and velocity at preferred speed (r = 0.11, P = 0.66), or fast 
gait speed (r =- 0.04, P = 0.87).  
 
 
Table 5. Odds ratio for velocity at normal gait speed for SCI and MCI, compared with controls 
Group OR (95% CI) P-value  
SCI (relative to control group)   
Age  1.03   (0.96 to 1.11)   0.38 
Velocity normal gait speed 
 
0.967 (0.938 to 0.997)   0.03 
Gender 1.07   (0.31 to 3.71)   0.92 
MCI (relative to control group)   
Age 1.07   (1.01 to 1.21)   0.02 
Velocity normal gait speed 0.963 (0.930 to 0.996)   0.03 
Gender 1.67   (0.40 to 7.01)   0.48 
Odds ratio estimated from the multinomial logistic regression model 
 
SCI: subjective cognitive impairment 
MCI: Mild cognitive impairment  
CI: Confidence interval  









Table 6. Odds ratio for velocity at fast gait speed for SCI and MCI, compared with controls 
Group OR (95% CI) P-value  
SCI (relative to control group)   
Age  1.04   (0.97 to 1.19)   0.30 
Velocity fast gait speed 
 
0.99   (0.97 to 1.01)   0.24 
Gender 1.11   (0.33 to 3.70)   0.87 
MCI (relative to control group)   
Age 1.11   (1.02 to 1.22)   0.02 
Velocity fast gait speed 0.971 (0.944 to 0.998)   0.03 
Gender 1.43   (0.33 to 6.18)   0.63 
Odds ratio estimated from the multinomial logistic regression model 
 
SCI: subjective cognitive impairment 
MCI: Mild cognitive impairment  
CI: Confidence interval 

















5.1 Method  
This thesis was a twofold. The literature review was first conducted to examine if there was an 
association between WR and cognitive impairment. Previous research has examined gait 
function in patients with cognitive impairment. So far, there has been paid little attention to the 
WR in this population. One study (Schwenk et al., 2014) included WR as one of the gait 
variables, but it was not the primary aim of the study. Therefore, a literature review for studies 
making it possible to calculate WR in cognitive impaired patients was needed. The second part 
of this thesis was a cross-sectional trial examining WR in pre-stages of dementia. Current 
evidence supports the existence of early stages of dementia (Fonseca et al., 2015), and it has 
been suggested that gait disorders are present even before memory impairment (Annweiler et 
al., 2012).  
 
5.1.1 Part 1 – literature review 
Literature search 
The literature search was conducted and structured with assistance of an experienced librarian. 
Additionally, studies were comprehended from other sources such as references lists to prevent 
missing relevant studies. However, it is still possible that suitable studies could be overlooked 
or missed.  
 
Study selection 
The literature review’s inclusion and exclusion criteria were vital for the study selection. Thus, 
different study designs were included in the review. The aim of the studies was of less 
importance because it was the only the baseline data themselves that would be included in the 
literature review. Follow-up data after interventions were not of interest because the data could 
be influenced by the intervention. The inclusion of the population had to be accounted for. In 
addition, the gait assessment had to be reliable and comparable between the studies.  
 
Several measures were implemented to ensure comparability. The included studies had 
professional physicians using current guidelines to diagnose the participants. Studies including 
neurological or orthopaedic patients were excluded for the sake of not influencing the results. 




was performed on an even floor level. Using data from different assessment might affect the 
results. The verbal instructions and the clinical setting would vary across studies and was not 
possible to correct for. However, all the studies used dynamic start and measured steady state 
walking. This excluded the deceleration and acceleration phases, making the results more 
comparable between studies. The number of meters walked varied between the studies. 
However, walking speed seems to be highly reliable in both community-dwelling and mixed 
setting studies (Rydwik et al., 2012) and Peters et al. (2013) stated that a 10-meter and 4-meter 
walk test had excellent agreement between the two tests when measuring gait speed.  
 
One of the studies measured fast gait speed (Schwenk et al., 2014) and not preferred gait speed. 
However, gait speed was not an inclusion criteria because WR is independent of gait speed 
(Rota et al., 2011, Sekiya et al., 1996). Two of the included studies (Coelho et al., 2013, 
Coelho et al., 2012) did not specify directly whether they measured steady state walking. They 
were after consideration included in the study because they both included step length and 
cadence as variables, indicating that they measured steady state walking, since otherwise 
information on step length and cadence would not have been unambiguous. Baseline data and 
follow up data were used in one of the longitudinal studies (Cedervall et al., 2014) and might 
influence the data as these participants were overrepresented in the analysis. However, this was 
an observational study without intervention and the participants (n=21) deteriorated both in 
MMSE score and in WR during the two year follow up.  
 
MMSE as a measure of cognitive impairment  
The MMSE-score was used as measure of cognitive impairment in the literature review.  
Of course, there are several other criteria than the MMSE when evaluating the degree of 
cognitive impairment and none of the studies used the MMSE-score alone for diagnosis. One 
problem with the MMSE is the low dynamic performance range for normal individuals. This 
increases the likelihood that patients in early stages of dementia scores within the normal range 
(Trzepacz et al., 2015). Franco-Marina et al. (2010) claims that ceiling effects of the test are 
often found in MCI and occur more frequently in people with high education. This is important 
to consider when interpreting the results, because the MMSE might not be sensitive enough to 
detect cognitive impairment in patients with low impairment and high education. It was not 
possible to correct for cofounders like education in the literature review, as this was not 




MCI from healthy controls (Lonie et al., 2009) and there is no firm consensus on the cut-off 
values used to distinguish disease severity (Gras et al., 2015). In addition, the MMSE-test was 
not designed to detect MCI patients (Pezzotti et al., 2008). However, the test is found to be 
valid, reliable and useful in quantitatively estimating the severity of cognitive impairment 
(Folstein et al., 1975, Petersen et al., 2001). Furthermore, MMSE was the best test for 
exploring associations with WR across studies as it is the most frequently used cognitive test in 
both clinical trials and in epidemiological studies (Franco-Marina et al., 2010). 
 
Generalizability of the result from the literature review  
Calculating new variables from published studies may provide uncertain and inaccurate results. 
The data were also taken from group means, and not individuals, leading to uncertain values 
since the mean of the individual ratios of two variables is not equal to the ratio of their means. 
Further, height and gender were not possible to adjust for in this part of the study since these 
data were not available. With higher age, women lose height more rapidly than men (Sorkin et 
al., 1999),  and this loss is mainly in the trunk area and does not affect leg length. Therefore, 
correcting for body height under the assumption that leg length is proportional to body height 
would result in a slight overcorrection returning a somewhat larger WR. Older women with 
reduced WR will therefore demonstrate WR closer to normal reference values. However, an 
unadjusted WR still gives an indication of association between WR and cognitive impairment 
for both men and women. Last, the results of this study were calculated from a total of 688 
participants across 16 studies. The high number of participants strengthens generalizability of 
the results.  
 
5.1.2 Part two – cross-sectional study  
Study design   
A cross-sectional design has limitations compared to a cohort design which would allow 
exploring changes over time. The results do not say anything about cause-effect. However, it is 
rather unlikely that locomotor behaviour influence cognitive function, but more likely, that 
cognitive function influence locomotor behaviour. In this trial, we only included participants in 
early stages of dementia and healthy controls. It would be preferable to have an AD group in 
addition to explore gait differences in a group with more severe cognitive impairment. Because 




studies have investigated motor function in SCI as one group. Tangen et al. (2014) investigated 
balance impairment in MCI and SCI but treated both MCI and SCI as one group. This is 
problematic because that would make a very heterogeneous group. Treating the participants 
with SCI as one group is a strength in this study. The cross-sectional trial has limitations as no 
power analysis was conducted, which makes it difficult to assess the generalizability to the 
MCI and SCI population due to possible type I and type II statistical errors. The MCI and SCI 
group were not compared to each other because a sharp demarcation between degrees of 
cognitive impairment is difficult as it relies on high test sensitivity (Jessen et al., 2014) and 
clinical judgement (Albert et al., 2011). In addition, there is a lack of consensus of cut-off 
values for distinguishing diagnosis on some of the cognitive tests (e.g. MMSE) which may lead 
to false-positive identifications (O'Bryant et al., 2008).   
Diagnostic process  
There are also sources of error related to the diagnostic process, as it not only depends on 
objective measures but also on clinical judgment (Albert et al., 2011). The outcome relied on 
the correct diagnosis and categorization of the patients. Albert et al. (2011) emphasize that the 
distinctions between normal cognition and different degree of dementia are difficult, thus, 
clinical judgement is important to make these distinctions. Kluger et al. (2008) suggested that 
the differences in findings between studies might be a result of the different definitions 
concerning MCI. Furthermore, previous research concerning SCI is limited by the lack of 
common standards (Jessen et al., 2014). A strength of our study is that the participants were 
diagnosed by an experienced geriatric physician according to current established guidelines 
(Albert et al., 2011). The trial had strict exclusion criteria in order to rule out cofounders that 
could interfere with the diagnostic process and with the gait assessment. However, cofounders 
might still be present. For instance, if all patients with some form of somatic pain or lack of 
sleep were excluded it would deeply affect the sample size and power of the study, even if 
these were conditions that theoretically could influence gait patterns.  
 
Gait assessment  
The same observer conducted the gait assessment throughout the trial, avoiding errors due to 
inter-rater reliability. A stopwatch was used for time measurement and the steps of the 
participants were counted. One might argue that counting the steps gives a rougher measure 
compared to an automatic gait analysis, which could provide data that are more exact. 




stopwatch for a 10-meter walk test when measuring velocity. The reliability and validity of a 
10-meter gait assessment is also found to be high (Peters et al., 2013). Studies have also found 
high test-retest reliability for gait speed in elderly adults (Rydwik et al., 2012, Steffen et al., 
2002). In additions, Sekiya & Nagasaki (1998) found that the WR is a reliable measure for 
evaluating walking patterns in pathological and aging populations. The observer for the gait 
assessment was not consistently blinded to the diagnosis of the participant, leading to possible 
bias. However, the main interest was the WR, which could not be obtained directly from the 
gait assessment but calculated afterword. Thus, it is not likely that the observer greatly affected 
the results during the gait assessment. The same verbal instructions were used for each of the 
participants. 
 
5.1.3 Comparability between the literature review and the cross-sectional trial   
The two different parts of this thesis investigate different aspects. Whilst the literature review 
only investigates the association between MMSE and WR, the cross-sectional trial explored 
how WR and other gait variables could predict cognitive impairment. The MMSE-scores used 
for cognitive assessment in the cross-sectional trial would not be suitable for analysis because 
the participant’s cognitive function was too high to make comparison between MMSE and 
WR. Still, the results from the different parts of this thesis could complement each other as 
they explore WR for different degrees of cognitive impairment. Combining these two 
approaches made it possible to examine WR both in a possible pre-stage of dementia and in 








5.2 Results  
5.2.1 Part 1 – results from the literature review  
The association between MMSE and walk ratio  
 
Our results showed a strong correlation between MMSE–score and WR in the total test 
population, also when excluding the healthy controls. The association between WR and the 
MMSE-score is interesting because WR usually is a constant value in normal healthy 
populations, independent of age, sex and gait speed (Egerton et al., 2011, Rota et al., 2011, 
Sekiya and Nagasaki, 1998, Sekiya et al., 1996). Sekiya et al. (1996) reports that a constant 
WR is followed by optimal stability in temporal and spatial parameters and a minimum of 
attentional demand during walking. A deviation from this constant might indicate an abnormal 
walking pattern (Sekiya and Nagasaki, 1998). Our results also showed that the healthy controls 
had statistically significant higher WR compared with the impaired group. The association 
between WR and MMSE is of importance as it may provide information on different gait 
strategies in cognitively impaired patients. As the severity of cognitive impairment increased, 
the gait pattern seemingly changes towards decreased step length and increased cadence. This 
may imply that WR is not constant in patients with cognitive impairment, as it supposedly is in 
healthy elderly. Few prior studies have examined WR in a cognitively impaired population. 
One study (Schwenk et al., 2014) measured a mean WR of 0.43 in patients with mild to 
moderate dementia, lower than Sekiya & Nagasaki’s (1996) proposed constant of 0.65. It has 
been reported that gait variables like step length (Gras et al., 2015, Shaw, 2002) and stride 
length (Nadkarni et al., 2009a, Nadkarni et al., 2009b) is lower in patients with various degree 
of AD compared to older healthy adults. This would yield a lower WR as long as there was no 
change in cadence and is consistent with our findings.  
 
Despite the lack of research on WR in a cognitively impaired population, other studies have 
found associations between gait impairments and the MMSE-score. A high MMSE-score 
appeared as an independent protective factor for gait impairment and a low MMSE-score was 
associated with balance and gait impairments in patients with AD (Mazoteras Munoz et al., 
2010). In addition, velocity is reported as an independent predictor of MMSE-score decline 
(Abellan van Kan et al., 2009). These findings support our results that there is an association 
between MMSE-score and gait impairments. Further, this could indicate that the severity of 




dysfunction increased the risk of cognitive impairment in elderly without known dementia 
(Verghese et al., 2002, Verghese et al., 2007). This is in agreement with our findings, as a 
lower MMSE-score associates with a lower WR.  
 
Gait dysfunction is more frequently reported with age and it have been reported that velocity 
decreases with age (Bohannon and Williams Andrews, 2011, Elble et al., 1992, Salzman, 2010) 
and that gait variables such as stance phase and stride with seem to increase with age. Salzman 
(2010) suggest that this might be an adaptation to changes in sensory or motor systems to 
increase gait stability. Elble et al. (1992) found that velocity and stride length were reduced 
between 17 - 20 percent in healthy elderly compared to young adults. Bohannon & Williams 
(2011) reported that velocity decreases each decade after 60 to 69 years. However, age did not 
explain the association between WR and MMSE in our study although our participants had a 
mean age of 75.9.  
 
Cognitive impairment and functional imaging  
 
Our results support the previous reported association between cognitive decline and gait 
impairment. These results are compelling because it has been generally accepted that the 
primary motor cortex has been less involved in AD (Brodal, 2007) and that motor dysfunction 
mostly is present in late or terminal stages of the disease (Suva et al., 1999). It is difficult to 
know whether the studies in the literature review included late stages of AD due to the different 
diagnostic processes. There are, however, evidence suggesting that there is a preclinical phase 
of AD, where pathological and functional imaging changes are present before individuals 
become symptomatic (Fonseca et al., 2015). The association between MMSE and WR found in 
our study implies that gait abnormalities vary with the degree of cognitive impairment. 
However, it remains unclear which brain structure and related lesions are specifically involved 
and could explain gait impairments (Annweiler et al., 2012). 
 
Gait impairment and falls  
 
The results from our literature review are also interesting because other studies have found that 
abnormal walking patterns could predict adverse outcomes such as falls. Other gait variables 
like stride variability and increased time in double support have been reported as predictors of 




and velocity among elderly with a history of falls. One study (Barak et al., 2006) found that 
elderly with a history of falls had higher cadence and shorter strides compared with non-fallers, 
which would indicate a lower WR. Changes in gait strategies may be a compensation for loss 
of gait stability, and a lower WR may be an adaption to the loss of stability. In addition, both 
dementia and cognitive impairment  are risk factors for falls (Shaw, 2002, van Doorn et al., 
2003) and they also have poorer prognosis for making a good recovery compared with 
cognitively normal patients (Shaw, 2002). The results from the literature review support other 
studies reporting that gait function may be impaired in dementia, and that interventions may be 
needed to avoid adverse outcomes such as falls.  
 
5.2.2 Part 2 – results from the cross-sectional trial  
Walk ratio and cognitive impairment  
 
The cross-sectional trial showed that WR was not able to predict SCI or MCI group 
membership when compared to healthy controls. Normally, WR remains constant at a value 
around 0.65 when adjusted for height (Sekiya et al., 1996). The mean WR for the three 
different groups were actually somewhat lower (Table 4). WR is a small entity with small 
variations and it could be that using an automatic gait analysis would be more accurate for 
measuring this entity. It is also possible that the power in this study was too small to detect a 
difference between controls and the two cognitive impairment groups. The results from the 
literature review indicated a linear relationship between WR and MMSE-score. There was little 
difference in MMSE-scores among the three groups in the cross-sectional trial. This was 
partially because MMSE was not the only test used for diagnosing the different groups. The 
MCI patients could score within normal range on the MMSE but lower on the other tests in the 
diagnostic process. Participants with SCI had to score within normal range of the MMSE, 
otherwise they would be diagnosed MCI. The mean MMSE-score in the literature review was 
much lower for the participants with cognitive impairment (mean 22.9 ± 3.3) compared to the 
mean MMSE-core of the MCI group (mean 27.8 ± 2.0) and the SCI group (mean 29.6 ± 0.6) in 
the cross-sectional trial. Considering that both MCI and SCI have high MMSE-scores, findings 
in our literature review indicate that WR would also be high. The results from the literature 
review may also imply that a decrease in WR would present itself in later stages of the disease. 
One study (Wittwer et al., 2010) found that patients with mild to moderate AD had 




difference in other gait variables. However, at the 12-month follow up the AD group showed a 
significant reduction in velocity, but also in stride length and an increase in time spent in 
double support. These findings may imply that gait variables might deteriorate later with 
disease progression.  
 
Decreased velocity predicts MCI and SCI group membership 
 
Our results found that there are significant differences in velocity even in the early stages of 
dementia compared with healthy controls. Decreased velocity at preferred gait speed predicted 
both MCI and SCI group membership. This is interesting because gait speed is found to be a 
predictor of adverse outcomes such as falls, cognitive decline and mortality (Abellan van Kan 
et al., 2009). These results could indicate that gait is impaired in very early stages of dementia. 
Current evidence still shows some inconsistency regarding various degrees of cognitive 
impairment and gait impairment. A cross-sectional trial (Pettersson et al., 2005) found 
impaired motor function in patients with very mild AD in performance-based tests, but not in 
MCI patients. However, they used clinical performance-based tests and did not measure gait 
variables directly. Studies have reported that velocity is decreased in patients with established 
AD compared to healthy controls, but there was no significant difference in velocity between 
MCI and healthy controls (Beauchet et al., 2013, Goldman et al., 1999). However, Maquet et 
al. (2010) found significant difference between gait speed in AD and MCI compared to 
controls in both single task and dual task. They also found an association between gait speed 
and MMSE-score. The patients with higher MMSE-score walked faster, which is interesting as 
our results from the literature review showed that a higher MMSE-score was associated with a 
higher WR.  
 
Some evidence suggests that motor impairment can predict cognitive decline. Aggerwal et al. 
(2006) found that lower limb impairment, measured by performance-based tests, in MCI 
patients were more likely to develop AD compared with to those without lower limb 
impairment. A longitudinal study (Buracchio et al., 2010) followed 204 healthy subjects older 
than 65 years old during16 years. They found that the participants that converted to MCI had a 
significant decrease in gait speed compared to the non-converters. More interestingly, among 
the MCI converters the decrease in gait speed started 12.1 years before the onset of MCI. One 
cohort (Wang et al., 2006) found an association between gait speed and future cognitive 




dementia during a 6-year follow up time for both MCI and healthy controls, indicating that gait 
impairment could be present even before the onset of memory impairment. These studies also 
support our findings that decreased gait speed might be present in very early stages of 
cognitive impairment, not only MCI but also SCI. This is of clinical relevance as the SCI 
patients without objective cognitive impairment seemingly have objective gait impairments. 
Further, these findings might be of relevance to the diagnostic process of these patients as they 
may be an early marker of cognitive impairment.  
 
Our study also showed that both decreased velocity at fast gait speed and age was predictive of 
MCI. Age is found to be a predictor of cognitive decline (Fonseca et al., 2015) and gait speed 
is known to decrease with age (Bohannon and Williams Andrews, 2011). However, it was no 
association between velocity and age in the MCI group. Velocity at fast gait speed is a 
relatively unexplored topic since most studies investigate preferred gait speed in cognitively 
impaired populations. However, Gras et al. (2015) found that patients with mild AD actually 
had significantly slower velocity at preferred gait speed, but not at fast gait speed compared 
with healthy adults. Another study found that higher stride-to-stride variability in stride time 
was a specific gait disturbance in MCI patients at fast gait speed (Beauchet et al., 2013). The 
MCI patients in our study were not able to increase their velocity to the same extent as the SCI 
group and the control group, which could imply a decline in physical capacity.  
 
The MCI group in our study had higher velocity at preferred gait speed compared with MCI 
patients in previous studies (Maquet et al., 2010, Wang et al., 2006, Muir et al., 2012). The 
reason for this might be due to differences in diagnostic processes or inaccurate measurement 
methods. A review (Graham et al., 2008) found that gait speed was higher when measuring 
steady state walking compared with static start, but the result did not reach statistical 
significance. However, the mentioned studies actually measured steady state walking, making 
it unlikely that the difference was due to a static or dynamic test protocol. It is also important to 
mention that one literature review (Abellan van Kan et al., 2009) found 1.0 meter per second as 
a cut point for increased risk of adverse outcomes. Thus, all our participants were within 
normal limits of velocity at preferred gait speed. However, there were still significant 
differences in gait speed between cognitive impaired and controls. Abellan Van Kan et al. 
(2009) suggested that an acceleration of decline in velocity might be an early warning for 
future cognitive decline. It is possible that it is the onset of an accelerated decline in velocity 





In addition to cognitive deterioration, a decrease in physical capacity may lead to further loss 
of independence for patients developing dementia. Walking is an important activity for 
mobility and participation in society (Rydwik et al., 2012). The loss of activities of daily living 
(ADL) capacity is a crucial problem for patients with AD (Gauthier et al., 1997) and may 
consequently be followed by adverse outcomes as institutionalization. Studies have found that 
AD patients’ ability to cope with ADL could be increased by improving their physical capacity 
regardless of their mental capacity (Rolland et al., 2007, Santana-Sosa et al., 2008). An early 
detection of gait impairment can contribute to intervention and possible prevention of further 
impairment. 
 
Subjective cognitive impairment and motor impairment  
 
To the best of knowledge, no previous studies have examined motor function in participants 
with SCI. The fact that there is a difference in velocity in the SCI group compared to healthy 
controls is interesting because it is a relatively unexplored population. Our results combined 
with previous research supports that gait velocity may be impaired in early stages of dementia, 
even before any memory impairments.  
 
Both SCI (Jessen et al., 2014) and MCI are risk factors for further cognitive decline (Jessen et 
al., 2014, Kluger et al., 2008). However, most of the people with such heterogeneous 
conditions will not deteriorate to dementia. Which of the subjects that will ultimately progress 
to develop dementia is unknown. It might be that differences in gait impairment can be seen 
between subjects that deteriorate and those who do not, not only in MCI and in SCI, but also 
healthy subjects.  
 
5.3 Clinical implications  
Dementia has a huge impact on function and quality of life, not just for the patients but also for 
the families affected. Early detection of patients with increased risk for dementia is important 
because it can provide early aid and interventions, such as physical interventions aimed to 
maintain physical independence as long as possible. As described, the onset of motor 
impairment might present itself years before the onset of memory impairments. Detecting 




non-specific marker of cognitive impairment. In addition, our results implied that WR 
decreases with cognitive impairment. Detecting gait abnormalities in dementia is important 
considering the possible increased risk of other adverse outcomes such as falls. A gait 
assessment, such as the 10-meter walk test, is also easy to perform and implement in a clinical 
setting.   
 
5.4 Future research   
The cross-sectional trial is a part of an ongoing cohort and further research will explore 
changes over time in both cognitive function and gait variables among the three groups. In 
addition, longer studies with larger samples are needed to support the findings of reduced 
velocity in patients with SCI and MCI, as there is limited resreach and some conflicting results 
on this topic. More research is needed to further investigate the relationship between WR and 
cognitive impairment not only in early stage dementia but also in established dementia. It 
would also be interesting to see if WR was affected by simultaneous cognitive tasks in early 
stages of cognitive impairment, since the dual-task-paradigm offers an approach to detect gait 







The results from the literature review showed that there was an association between WR and 
the MMSE-score in patients with various degree of dementia. This could indicate an 
association between the degree of cognitive impairment and WR and that movement strategies 
change with increased cognitive impairment. Our cross-sectional trial found no difference in 
WR between controls and the cognitive impairment groups, indicating that there was no 
difference in movement strategy between the groups. However, decreased velocity at preferred 
gait speed was predictive of both MCI and SCI. In addition, the MCI group walked 
significantly slower at fast gait speed. It seems like both SCI and MCI use the same strategy 
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Forespørsel om deltakelse i prosjektet 
”Når  hukommelsen svikter” 
 
Bakgrunn og hensikten  
Hensikten med prosjektet er å kartlegge risikofaktorer forbundet med nevrologiske 
sykdommer og undersøke hvorfor hukommelsesvansker og andre kognitive problemer 
oppstår. Alzheimers sykdom og Parkinsons sykdom er sykdommer vi ønsker å fokusere 
spesielt på, særlig i tidlig fase.  
 
Hvor mange med disse og andre hjernesykdommer vil utvikle kognitiv svikt? Kognisjon er 
summen av ulik hjerneaktivitet, slik som hukommelse, læring, minner, språk og 
orienteringsevne. Generelt er det økt sannsynlighet for at pasienter med en hjernesykdom vil 
utvikle kognitiv svikt hvis sykdommen er av kronisk natur. Kognitive vansker kan oppstå 
tidlig i et sykdomsforløp med få eller ingen samtidige fysiske symptomer, men det finnes 
også flere andre debutsymptomer utover kognitiv svikt som kan dominere.   
 
Et overordnet mål for prosjektet er derfor å bedre diagnostikk og behandling av pasienter med 
hjernesykdom som allerede har eller har økt sjanse for å utvikle kognitive problemer.  
 
Studien er et nasjonalt samarbeid der de enkelte institusjonene som deltar er ansvarlige for 
studien og sin del av biobanken. Deltakende institusjoner i Norge er Akershus 
universitetssykehus, Oslo universitetssykehus, Stavanger universitetssykehus, Helse Fonna, 
St. Olavs hospital og Universitetssykehuset i Nord-Norge. I tillegg deltar Gøteborgs 
universitet i Sverige. Prosjektleder og overordnet ansvarlig er professor Tormod Fladby ved 
Akershus universitetssykehus.  
 
H va innebærer  studien 
Du blir forespurt fordi du opplever å ha vansker med hukommelsen eller har en annen nedsatt 
kognitiv funksjon, eller har en tilstand som er forbundet med risiko for å utvikle dette. Du kan 
også bli forespurt om å delta som kontrollperson, dersom du er ektefelle eller samboer med 
noen som har nedsatt kognitiv funksjon.  
 
F or deg som pasient vil deltakelse i prosjektet innebære analyser av blod og 
ryggmargsvæske, tester av kognitiv funksjon og bilder av hjernen (MR). Utover dette ønsker 
vi å kartlegge ulike kroppslige symptomer ved en grundig legeundersøkelse samt eventuelle 
depressive plager, søvnvansker og viktige funksjoner i dagliglivet for øvrig. Samtidig som de 
diagnostiske prøvene blir tatt, blir det tatt ekstra rør med ryggmargsvæske og blod som blir 
lagret i en forskningsbiobank. Dersom det blir restmateriale etter diagnostisk analysering, vil 
dette restmateriale også bli lagret i biobanken. Det vil bli tatt blodprøver for analyse av 
arvematerialet (DNA og RNA). Disse analysene vil ikke ha noen diagnostisk verdi for deg 
som deltaker og det vil derfor ikke bli gitt genetisk veiledning.  
 
For noen pasientgrupper vil det være aktuelt å tilby utvidede rutineundersøkelser; 
Nevropsykologisk undersøkelse som innebærer testing av kognitive funksjoner (f. eks 
hvordan man husker eller konsentrerer seg ved forskjellige oppgaver) og skanning av hjernen 
som kartlegger aktivitetsfordelingen i ulike deler av hjernen (PET). Redusert aktivitet forteller 
noe om nedsatt eller endret hjernefunksjon.  PET-skanning tar omtrent 20 minutter, og 
medfører ikke risiko eller ubehag utover det som er vanlig ved en vanlig hjerne 
skanningsundersøkelse (CT/MR). Søvnregistrering vil være aktuelt for pasienter med 
spesifikke søvnforstyrrelser. Dette foregår ved såkalt polysomnografi over natten hvor 











Samtykke_DDI_09.04.13 v1.1                              2 
F or deg som er kontrolldeltaker vil eventuell deltakelse medføre blodtrykksmåling, 
blodprøvetaking, enkel testing av kognitive funksjoner, ovennevnte hjerneskannings 
undersøkelse (MR og PET) og eventuelt en ryggmargsvæskeundersøkelse. Denne 
undersøkelsen kan for noen oppleves som en ulempe, men en kontrolldeltaker kan selv velge 
å delta i studien, med eller uten ryggmargsvæskeundersøkelse. Det er liten risiko for 
bivirkninger og ubehagelige følgetilstander som forbigående hodepine mv. i denne 
aldersgruppen (kun 2.6 % rapporterer mild hodepine etter punksjon, Zetterberg et al., 2010). 
Muntlig informasjon om gjennomførelsen av ryggmargsvæskeundersøkelse vil bli gitt av 
studielege. Det vil bli tatt blodprøver for analyse av arvematerialet (DNA og RNA). Disse 
analysene vil ikke ha noen diagnostisk verdi for deg som deltaker og det vil derfor ikke bli 
gitt genetisk veiledning.  
 
Fordelen med å inkludere friske kontroller er at deltakelsen kan gi økt forståelse av 
nevrologiske prosesser i normal aldring. Hittil har det vært mange studier som har inkludert 
pasienter med kognitiv svikt, men få som kan sammenligne med et representativt 
kontrollmateriale.  
 
Mellom to til tre år etter at du ble inkludert i forskningsprosjektet, vil vi innkalle deg som 
deltar, som pasient eller kontrolldeltaker, inn til en oppfølgingsundersøkelse. I denne 
undersøkelsen vil det bli gjennomført ny hjerne skannings undersøkelse (MR/PET), samt ny 
kartlegging av kognitive funksjoner og nye blodprøver. Dette vil også bli en klinisk 
kontrolltime der vi vurderer utviklingen av tilstanden, og om det eventuelt er noe i 
behandlingen som bør endres. 
 
M ulige fordeler  og ulemper 
Hvis du velger å bli med i prosjektet, vil du få en grundigere utredning enn det som vanligvis 
er tilgjengelig, og du vil også bli fulgt opp med kontrollundersøkelser av fagpersoner med 
spisskompetanse innen dette feltet. Dette medfører at du da må gjennomgå flere undersøkelser 
enn ellers. Analyser i blod og ryggmargsvæske, tester av kognitiv funksjon og bilder av 
hjernen (MR/PET), kan i fremtiden bidra til bedre diagnostikk og bedre 
behandlingsmuligheter. Ved behov vil du få tilbud om behandling eller henvisning til andre 
spesialister. 
 
H va skjer  med prøvene og informasjonen om deg? 
Prøvene tatt av deg og informasjonen som registreres om deg, vil kun brukes slik som 
beskrevet i hensikten med studien. Alle opplysningene og prøvene vil bli behandlet uten navn 
og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til 
dine opplysninger og prøver gjennom en navneliste. Det er kun autorisert personell knyttet til 
prosjektet som har adgang til navnelisten og som kan finne tilbake til deg. Det vil ikke være 
mulig å identifisere deg i resultatene av studien når disse publiseres. Etter prosjektets slutt vil 




Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. 
Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste side. Om du nå sier 
ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige 
behandling. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan du 
kontakte din lokale kontaktperson eller prosjektleder Tormod Fladby ved Nevroklinikken, 
Akershus universitetssykehus på telefon 67 96 95 27. 
 
Personvern 
Opplysninger som registreres om deg er journalopplysninger fra gjeldende utredning og/eller 
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underlagt taushetsplikt og behandles i henhold til datatilsynets retningslinjer. Du har rett til 
innsyn i hvilke opplysninger som er registrert om deg. Du kan kreve å få slettet 
opplysningene om deg dersom du ønsker det. Databehandlingsansvarlig er 
forskningsansvarlig ved den enkelte institusjon.  
 
Biobank 
Ryggmargsvæske- og blodprøvene som blir tatt vil bli lagret i en nasjonal forskningsbiobank 
(DDI - dementia disease initiative). Hvis du sier ja til å delta i studien, gir du også samtykke 
til at det biologiske materialet inngår i biobanken og fritt kan sendes mellom institusjonene 
som deltar i prosjektet. Prosjektleder Tormod Fladby er ansvarshavende for 
forskningsbiobanken. Biobanken planlegges å vare til 31.12.2025. Etter dette vil materiale bli 
destruert og opplysninger vil bli anonymisert slik at det ikke lenger vil være mulig å knytte 
deg til opplysningene, dette etter interne retningslinjer.  
 
Utlever ing av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at avidentifiserte prøver og 
avidentifiserte opplysninger er tilgjengelig for alle samarbeidspartnere i denne 
multisenterstudien. Dersom materiale sendes til utlandet (Gøteborg, Sverige) vil dette alltid 
skje i tett samarbeid med og under ledelse av den norske prosjektledelsen. 
 
Rett til sletting av prøver 
Hvis du sier ja til å avgi biologisk materiale til biobanken, har du rett til å få innsyn i hvilke 
prøver som er registrert på deg. Dersom du ønsker å trekke tilbake samtykket kan du kreve å 
få destruert innsamlede prøver, med mindre materialet allerede er inngått i analyser er brukt i 
vitenskapelige publikasjoner.  
 
Økonomi 
Studien er finansiert gjennom forskningsmidler fra Norges Forskningsråd. 
 
Forsikr ing 
Ved deltakelse i studien er deltakelsen dekket av norsk pasientskadeerstatning. 
 
I nformasjon om utfallet av studien 
Du som deltaker har rett til å få informasjon om utfallet/resultatet av studien. Dersom du 
ønsker det, kan du få opplyst hvilke publikasjoner som er skrevet på grunnlag av prosjektet. 
Det er opprettet en hjemmeside for prosjektet der resultater vil bli presentert etter hvert som 
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Samtykke til deltakelse i studien 
 




Jeg har mottatt skriftlig og muntlig informasjon angående studien  
”Når hukommelsen svikter” 
 
























































































































































Search strategy  
 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
<1946 to Present> 
13. March 2015 
 
1     (((step length or stride length) and (cadence or step frequency)) or ((gait or walk) adj1 
(speed or velocity)) or walk ratio).tw. (3382) 
2     exp Dementia/ (123008) 
3     Mild Cognitive Impairment/ (2687) 
4     (dement* or alzheimer* or mild cognitive impairment).tw. (143746) 
5     2 or 3 or 4 (176151) 
6     1 and 5 (142) 
 
 
7     (walking or gait or walk).tw. (82535) 
8     Gait/ or Walking/ (35194) 
9     7 or 8 (91539) 
10     5 and 9 (2376) 
 
 
Database: (Ovid) Embase <1974 to 2015 March 12> 
13. March 2015 
 
1     (((step length or stride length) and (cadence or step frequency)) or ((gait or walk) adj1 
(speed or velocity)) or walk ratio).tw. (4567) 
2     exp dementia/ (240302) 
3     mild cognitive impairment/ (11231) 
4     (dement* or alzheimer* or mild cognitive impairment).tw. (190050) 
5     2 or 3 or 4 (272867) 







Database: Ovid AMED (Allied and Complementary Medicine) <1985 to March 2015> 
13. March 2015 
 
1     (((step length or stride length) and (cadence or step frequency)) or ((gait or walk) adj1 
(speed or velocity)) or walk ratio).tw. (887) 
2     exp dementia/ (2200) 
3     mild cognitive impairment/ (13) 
4     (dement* or alzheimer* or mild cognitive impairment).tw. (2920) 
5     2 or 3 or 4 (2920) 
6     1 and 5 (8) 
 
 
Database: Ovid PsycINFO <1806 to March Week 2 2015> 
13. March 2015 
 
1     (((step length or stride length) and (cadence or step frequency)) or ((gait or walk) adj1 
(speed or velocity)) or walk ratio).tw. (694) 
2     exp dementia/ (55715) 
3     (dement* or alzheimer* or mild cognitive impairment).tw. (74190) 
4     2 or 3 (75209) 
5     1 and 4 (66) 
 
Comment: Mild cognitive impairment is not a mesh term I PsycINFO. Mesh term «Cognitive 
impairment» is to wide. 
 
 
Cochrane library (Wiley)  
13. March 2015 
 
#1 (((step length or stride length) and (cadence or step frequency)) or ((gait or walk) 
near/1 (speed or velocity)) or walk ratio):ti,ab,kw  (Word variations have been searched) 1957 
#2 (dement* or alzheimer* or mild cognitive impairment):ti,ab,kw  (Word variations 
have been searched) 9394 





13 of March 2015  
(((step length or stride length) and (cadence or step frequency)) or ((gait or walk) near/1 (speed 





step length AND cadence 
 
stride length AND cadence 
 



















combined with  
 
dement* or alzheimer* or mild cognitive impairment) 
 
Combinations: 
"step length" cadence dement* 
 
"step length" cadence alzheimer* 
 
"step length" cadence "mild cognitive impairment" 
 
 
stride length AND cadence dement 
 
stride length AND cadence alzheimer* 
 
stride length AND cadence "mild cognitive impairment 
 
step length AND step frequency dement* 
step length AND step frequency alzheimer* 
step length AND step frequency "mild cognitive impairment" 
 
stride length AND step frequency dement* 
stride length AND step frequency alzheimer* 
stride length AND step frequency "mild cognitive impairment" 
 
gait speed dement* (3) 
gait speed alzheimer* 
gait speed "mild cognitive impairment" (1) 
 
gait velocity dement*(1) 
gait velocity alzheimer* 
gait velocity "mild cognitive impairment" 
 




walk speed alzheimer* 
walk speed "mild cognitive impairment" 
 
walk velocity dement* 
walk velocity alzheimer* 
walk velocity "mild cognitive impairment" 
 
walk ratio dement* (1) 
walk ratio alzheimer* 
walk ratio "mild cognitive impairment" 
 
Total 5  
 
 
 
 
